Submit Manuscript  

Article Details


Anti-angiogenic Agents: A Review on Vascular Endothelial Growth Factor Receptor-2 (VEGFR-2) Inhibitors

Author(s):

Kang Cheng, Chen-Fu Liu and Guo-Wu Rao*   Pages 1 - 24 ( 24 )

Abstract:


Tumor growth inhibition can be achieved by inhibiting angiogenesis, which has been a field of great concern in recent years. Important targets to inhibit angiogenesis include vascular endothelial growth factor receptor (VEGFR) and its homologous tyrosine kinase receptor. Anti-angiogenic therapy based on inhibition of VEGFR-2 is an effective clinical treatment strategy. The research progress of VEGFR-2 inhibitors is reviewed in this paper from the aspects of the drug development and chemical synthesis.

Keywords:

Tumor, Anti-angiogenic agents, Tyrosine kinase, VEGFR-2 inhibitor, Approved drugs, Synthesis.

Affiliation:

College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014, School of Pharmaceutical Sciences, Gannan Medical University, Ganzhou 341000, College of Pharmaceutical Science, Zhejiang University of Technology, and Institute of Drug Development & Chemical Biology, Zhejiang University of Technology, Hangzhou 310014



Read Full-Text article